PRESS RELEASE BETHESDA.

Said Janet A. Silvester, Pharm.D., M.B.A., FASHP, ASHP Vice President of Accreditation Services. ASHP will periodically upgrade these guidance files as feedback and new questions arise. Suggestions and Questions could be directed to the ASHP Accreditation Services Office in .. PRESS RELEASE BETHESDA, MD—ASHP has released two new assistance documents and online training opportunities related to the new ASHP Accreditation Regular for Postgraduate Year One Pharmacy Residency Applications . These resources aim to improve transparency and consistency in the residency accreditation procedure and provide easy to get at training possibilities for residency programs.

Persing, M.D., Ph.D., Sabine Ruesch-Gerdes, M.D., Eduardo Gotuzzo, M.D., Camilla Rodrigues, M.D., David Alland, M.D., and Mark D. Perkins, M.D.: Quick Molecular Detection of Rifampin and Tuberculosis Resistance Only a part of the estimated 500,000 patients who’ve multidrug-resistant tuberculosis and 1.37 million patients who have coinfection with tuberculosis and the human immunodeficiency virus worldwide every year have access to sufficiently sensitive case recognition or drug-susceptibility testing.1 Diagnostic delay, aggravated by the disproportionate frequency of smear-harmful disease in HIV-associated tuberculosis, is common.2-5 The failure to recognize and treat affected patients leads to increased mortality quickly, secondary resistance , and ongoing transmission.Persing, M.D., Ph.D., Sabine Ruesch-Gerdes, M.D., Eduardo Gotuzzo, M.D., Camilla Rodrigues, M.D., David Alland, M.D., and Mark D. Perkins, M.D.: Quick Molecular Detection of Rifampin and Tuberculosis Resistance Only a part of the estimated 500,000 patients who’ve multidrug-resistant tuberculosis and 1.37 million patients who have coinfection with tuberculosis and the human immunodeficiency virus worldwide every year have access to sufficiently sensitive case recognition or drug-susceptibility testing.1 Diagnostic delay, aggravated by the disproportionate frequency of smear-harmful disease in HIV-associated tuberculosis, is common.2-5 The failure to recognize and treat affected patients leads to increased mortality quickly, secondary resistance , and ongoing transmission.